CE vs DMAC
Celanese Corporation (CE) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
Celanese Corporation (CE) is a chemicals company listed on US.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
DMAC does not have a complete income-statement cache yet.
CE currently screens at market cap $5.92B. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the CE and DMAC stock pages for the full models.
Not investment advice.